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Introduction
With the improvement of HAART, life expectancy of
HIV-infected patients sharply increased. The incidence
of cancerous diseases is therefore increasing in this
population. This raises the problem of drug-drug inter-
actions between HIV treatment and cancer chemother-
apy poorly understood because few data are available.
However, the potential risk of interactions is important
because of the involvement of similar metabolic
enzymes and transporters between these drugs and due
to the inhibitory and/or inducer effects on different
CYP450 isoforms of the PI and NNRTI. These interac-
tions may both lead to inefficiency and/or an increased
risk of toxicity of the chemotherapy which can be life-
threatening for the patient.
Materials and methods
We set up since January 2010 amultidisciplinary staff
“AIDS-cancer-transplantation” to optimize the manage-
ment of HIV-infected patients diagnosed for a tumour
disease. Demographic, virological and immunological
characteristics and therapeutic decision issued from the
staff for these patients have been retrospectively
analyzed.
Results
As of today, data of 28 patients have been evaluated. A
therapeutic adjustment had to be proposed for 14
patients (50%), mainly corresponding to a modification
of the antiretroviral therapy (11/14). The new cART
therapeutic option was defined according to HIV
resistance profile, ART history and after additional bio-
logical analyzes if requested. In few cases (4/14), the
cancer chemotherapy was adjusted according to the dif-
ferent therapeutic options proposed. The main reasons
for such therapeutic adjustment were, for 57% (8/14),
related to a metabolic interaction through the CYP3A4
because of the presence of a boosted PI or NNRTI and
for 36% (5/14) to an increased risk of nephrotoxicity
due to the concomitant administration of tenofovir with
a potent nephrotoxic anticancer drug.
For all patients, opportunistic infections prophylaxis
(PCP) and screening for PCR CMV have been pre-
scribed according to French recommendations.
Conclusion
The implementation of the multidisciplinary staff
“AIDS-cancer-transplantation” highlights a high fre-
quency of the risk of drug interactions between antire-
trovirals and antitumoral agents. This allows us to
optimize the management of HIV patients treated for
malignant diseases by apprehending the risk of drug
interactions.
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